Evidence map›Paper›PMID 29523331›Full record

ReviewTuberculosis (Edinburgh, Scotland)2018

The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs.

Christine Sekaggya-Wiltshire, Mohammed Lamorde, Agnes N Kiragga, Kelly E Dooley, Moses R Kamya, Andrew Kambugu, Jan Fehr, Yukari C Manabe, Barbara Castelnuovo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Tuberculosis (Edinburgh, Scotland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2020
    Pooled it
  2. Article
  3. Multidrug-resistant tuberculosis.Nature reviews. Disease primers · 2024
    Review
  4. Article
  5. Article
  6. Clinical impact of plasma concentrations of first-line antituberculosis drugs.South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde · 2023
    Article
  7. Review
  8. Article
  9. Subtherapeutic Rifampicin Concentration Is Associated With Unfavorable Tuberculosis Treatment Outcomes.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christine Sekaggya-WiltshireInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. Electronic address: csekaggya@idi.co.ug.
Mohammed LamordeInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Agnes N KiraggaInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Kelly E DooleyDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA.
Moses R KamyaSchool of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Andrew KambuguInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Jan FehrDivision of Infectious Diseases and Infection Control, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Yukari C ManabeDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA.
Barbara CastelnuovoInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.

Funding

Fogarty Global Health Fellows Coordinating CenterR25TW009340 · FIC · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHI, BENJAMIN H. · 2012 to 2016
$6.9M
FIC NIH HHS R25 TW009340
6 · The paper itself

Abstract

Tuberculosis (TB) is a major public health problem. Many countries still fall below the minimum World Health Organization (WHO) TB treatment target success rate. There is conflicting evidence about whether concentrations of anti-tuberculosis drugs given at standard doses have an effect on treatment outcomes. The current data correlating anti-TB drug concentrations and treatment outcome is limited. This article summarized the existing literature and their utility in evaluating the association between each anti-TB drug's concentrations using current target concentrations and treatment outcomes in patients with pulmonary tuberculosis receiving standard WHO-recommended dosing.

Indexed as

Antitubercular AgentsDose-Response Relationship, DrugDrug Dosage CalculationsDrug MonitoringHumansModels, BiologicalMycobacterium tuberculosisTreatment OutcomeTuberculosis, PulmonaryAntitubercular AgentsAnti-tuberculosis drugsConcentrationsTreatment outcomes

Identifiers

PMID29523331
PMCPMC5846119

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.